Rising clinical trial complexity continues to vex drug developers, says Tufts

Growing clinical trial complexity continues to challenge the ability of pharmaceutical and biotechnology companies to contain the ever-rising cost of developing new drugs, according to a study recently completed by the USA-based Tufts Center for the Study of Drug Development.

The study found that the median number of procedures per clinical trial increased by 49% between 2000-03 and 2004-07, while the total effort required to complete those procedures grew by 54%. The new study updates an analysis conducted by Tufts CSDD two years ago, which provided the first quantitative assessment of the impact of protocol design on clinical trial performance.

"More complex and burdensome protocols are extending study cycle times, increasing costs, and challenging patient recruitment and retention," said Tufts CSDD senior research fellow Ken Getz, who conducted the study. "Wide observed differences in complexity and execution burden by phase and therapeutic area indicate that pharmaceutical and biotechnology companies can target their efforts to improve protocol design and improve clinical trial operating performance," he added.